Financial Guidance and Company Overview
Transaction Overview
Consideration
•
Funding & Leverage
•
Timing
$5.60 per share in cash at closing
Total transaction value: ~$960mm
Majority funding through existing cash, supplemented with new sources of low-cost bank debt
Transaction not subject to any financing condition
Expect leverage to be <3.5x net debt to EBITDA ratio at time of close. Leverage expected to decline
significantly in the quarters post-close
•
Unanimously approved by boards of directors of both companies
•
Closing expected in first half 2022
Subject to completion of tender offer for acquisition of majority of shares, HSR review, and other
customary closing conditions
Financial Impact
Expected to be immediately accretive to revenue and non-GAAP EPS
Enhances long-term growth prospects and revenue durability
Halozyme
6View entire presentation